Monitor for actual sales execution in the coming days, as coordinated Form 144 filings from major early investors may signal reduced confidence or capital reallocation. Given the $2.9M scale and recent insider selling trend, consider increased downside risk ahead of potential supply pressure.
Price Chart
Executive Summary
Two affiliated venture funds, Atlas Venture Fund XI and Atlas Venture Opportunity Fund I, filed Form 144 notices to sell a combined 198,926 shares of Dyne Therapeutics stock, representing an intent to sell approximately $2.9 million worth of shares. The sales are planned under Rule 144 following private placement acquisitions in 2020.
Key Facts
- Atlas Venture Fund XI filed to sell 142,571 shares, valued at approximately $2.05 million based on recent market price
- Atlas Venture Opportunity Fund I filed to sell 56,355 shares, valued at approximately $815,000
- Total proposed sale: 198,926 shares worth ~$2.87 million
- Shares were acquired in private placements in July and August 2020
- Sales are being conducted through Merrill Lynch in San Francisco
- Both filings were submitted on the same day (April 20, 2026), indicating coordinated action
Financial Impact
$2.87 million in planned insider sales from two affiliated venture funds
Risk Factors
- Potential downward pressure on stock price if sales are executed rapidly
- Signal of waning confidence from early institutional investors
- Increased share supply in a potentially illiquid biotech stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (DYN) — Batch item 1 | 0001628280-26-026024 |
| Document: 0001628280-26-026024-index.html | 0001628280-26-026023 |
| Document: 0001628280-26-026024.txt | 0001628280-26-026024 |
| 144 Filing (DYN) — Batch item 4 | 0001628280-26-026023 |
| Document: 0001628280-26-026023-index.html | 0001628280-26-026024 |
| Document: 0001628280-26-026023.txt | 0001628280-26-026024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access